Dublin, Dec. 15, 2017 -- The "Global RNA Sequencing Market - Forecasts from 2017 to 2022" report has been added to Research and Markets' offering.
The global RNA sequencing (RNA-Seq) market is projected to witness a significant growth rate during the forecast period, growing at a CAGR of 12.07% during the forecast period to reach a total market size of US$3.692 billion by 2022, increasing from US$1.863 billion in 2016.
Viral evolution and increasing incidence of genetic disorders have elevated the need for technical advancements in RNA sequencing products which are expected to drive the market over the projected period. Increasing grants for RNA sequencing have led to increasing number of research activities involving RNA sequencing. However, lack of skilled professionals required for RNA sequencing will impede the market growth. Moreover, strict government regulations in some regions will further slow down the growth rate of the market.
The major players discussed in this report include Illumina, Inc., Macrogen Inc., GATC Biotech AG., Eurofins Scientific, PerkinElmer Inc., and Oxford Nanopore Technologies among few others.
Segmentation
By Technology
- Ion Semiconductor Sequencing
- Single-Molecule Real-Time (SMRT) Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis (SBS)
By Applications
- Small RNA Sequencing
- Expression Profiling Analysis
- De Novo Transcriptome Assembly
- Variant Calling and Transcriptome Epigenetics
By End-User
- Research Centers
- Biotechnology Labs
- Healthcare Centers
- Others
Companies Mentioned
- Illumina, Inc.
- Macrogen Inc.
- GATC Biotech AG.
- Eurofins Scientific
- PerkinElmer Inc.
- Oxford Nanopore Technologies
- BGI (Beijing Genomics Institute)
- Pacific Biosciences of California, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/3x34cc/global_rna?w=12
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics


DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Anta Sports Expands Global Footprint With Strategic Puma Stake
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Washington Post Publisher Will Lewis Steps Down After Layoffs
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



